Cullinan Oncology to Host Analyst and Investor Briefing at 2022 ASCO Annual Meeting
May 26 2022 - 7:45AM
Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a
biopharmaceutical company focused on developing a diversified
pipeline of targeted therapies for patients with cancer, today
announced that it will host an investor and analyst briefing during
the 2022 American Society of Clinical Oncology (ASCO) Annual
meeting to review updated data from its lead program,
CLN-081/TAS6417.
The briefing will be held on Saturday, June 4, 2022 at 8:00 a.m.
EDT (7:00 a.m. CDT), and will be available under the Events section
of the Company’s investor relations website at
https://investors.cullinanoncology.com/news-events/events.
The briefing will feature a review of updated data from the
ongoing Phase 1/2a Study of CLN-081/TAS6417 in non-small cell lung
cancer patients with EGFR Exon 20 insertion mutations (Ins20),
which are being presented during an ASCO oral abstract session on
June 3, 2022 (Abstract number 9007).
CLN-081/TAS6417 is an orally available,
differentiated, irreversible EGFR inhibitor that selectively
targets cells expressing EGFR exon 20 insertion mutations while
sparing cells expressing wild-type EGFR. Cullinan recently
announced a strategic collaboration with Taiho Pharmaceutical Co.,
Ltd. for the joint development and commercialization of
CLN-081/TAS6417.
About Cullinan Oncology Cullinan Oncology, Inc.
(NASDAQ: CGEM) is a biopharmaceutical company dedicated to creating
new standards of care for patients with cancer. We innovate without
borders to find the most promising clinic-ready cancer therapies,
whether from our own discovery efforts or through exceptional
engagement with our academic and industry partners. Anchored in a
deep understanding of immuno-oncology and translational cancer
medicine, we leverage our scientific excellence in small molecules
and biologics to create differentiated ideas, identify unique
targets, and select the optimal modality to develop transformative
therapeutics across cancer indications. Powered by our novel
research model, we push conventional boundaries from candidate
selection to cancer therapeutic, applying rigorous early
experimentation to fast-track only the most promising assets to the
clinic and ultimately commercialization. As a result, our
diversified pipeline is strategically built with assets that
activate the immune system or inhibit key oncogenic drivers across
a wide range of modalities, each with the potential to be the best
or first in their class.
Our people possess deep scientific expertise, seek innovation
openly, and exercise creativity and urgency to deliver on our
promise to bring new therapeutic solutions to patients with cancer.
Learn more about our Company at www.cullinanoncology.com, and
follow us on LinkedIn and Twitter.
Contacts: Investor Relations Chad Messer+1
203.464.8900cmesser@cullinanoncology.com
MediaRose Weldon+1 215.801.7644rweldon@cullinanoncology.com
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cullinan Therapeutics (NASDAQ:CGEM)
Historical Stock Chart
From Jul 2023 to Jul 2024